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Abstract
The American Recovery and Reinvestment Act of 2009 (ARRA), the stimulus package signed into law by
President Barack Obama on February 17, 2009, directs $1.1 billion to support “the development and
dissemination of research assessing the comparative effectiveness of health care treatments and strategies,
including through efforts that . . . conduct, support, or synthesize research that compares the clinical
outcomes, effectiveness, and appropriateness of items, services, and procedures that are used to prevent,
diagnose, or treat diseases, disorders, and other health conditions.”
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The American Recovery and Reinvestment Act of 2009 
(ARRA), the stimulus package 
signed into law by President 
 Barack Obama on February 17, 
2009, directs $1.1 billion to sup-
port “the development and dis-
semination of research assessing 
the comparative effectiveness of 
health care treatments and strat-
egies, including through efforts 
that . . . conduct, support, or 
synthesize research that com-
pares the clinical outcomes, effec-
tiveness, and appropriateness of 
items, services, and procedures 
that are used to prevent, diagnose, 
or treat diseases, disorders, and 
other health conditions.”
The rationale for seeking bet-
ter information on comparative 
effectiveness is well understood. 
Many existing devices and thera-
peutic approaches have never been 
subjected to the scrutiny of ran-
domized, controlled trials com-
paring them with placebos, and 
even fewer have been directly 
tested against other approaches 
to improving the health of people 
with a given condition. Though 
there is controversy over whether 
such evaluations should include 
information on cost-effectiveness 
and how the findings should be 
used in coverage decisions, there 
is little debate that both health 
care professionals and the pub-
lic will benefit greatly from bet-
ter data to inform their choices 
among the available therapies for 
a given condition.
In considering the allocation 
of federal resources for compara-
tive-effectiveness research (CER), 
however, it is important that we 
maintain a broad view of ways of 
improving the health of the pop-
ulation. As many as 40% of pre-
mature deaths in the United States 
are attributable to Americans’ own 
health-related behaviors. If CER’s 
full potential for improving the 
population’s health is to be real-
ized, such comparisons must go 
beyond those between medication 
A and medication B or device A 
and device B: we must also assess 
medications or devices in compar-
ison with behavioral interventions, 
either alone or in conjunction 
with other approaches. In addi-
tion, since many diverse aspects 
of care delivery have a direct effect 
on patients’ health outcomes, we 
should assess policy-based inter-
ventions and their relative effec-
tiveness in improving health.
In many cases, it seems clear 
that patients’ individual health-
related behaviors are the proxi-
mate cause of disease and of the 
need for medical treatments. For 
example, obesity is a major risk 
factor for hypertension, diabetes, 
lower back pain, and other con-
ditions. Patients who are able to 
lose weight may be able to re-
duce or eliminate their use of 
medications for these conditions. 
It therefore makes sense to com-
pare, among patients with diabe-
tes, medication-based approaches 
to the treatment of diabetes with, 
for example, the effects of be-
havioral approaches to weight 
reduction.
One of the best-known ran-
domized, controlled trials com-
paring a lifestyle intervention with 
medical therapy, the Diabetes Pre-
vention Program, showed that 
over a mean follow-up period of 
2.8 years, intensive lifestyle ther-
apy was significantly more effec-
tive than metformin therapy in 
preventing the onset of diabetes 
among persons without diabetes 
who, at enrollment, had elevated 
fasting and elevated post-load 
plasma glucose levels.1 The inci-
dence of diabetes was 11.0, 7.8, 
and 4.8 cases per 100 person-
years in the placebo, metformin, 
and lifestyle-intervention groups, 
respectively, meaning that the 
lifestyle intervention reduced the 
incidence of diabetes by 58% (95% 
confidence interval [CI], 48 to 66), 
and metformin reduced the inci-
dence by 31% (95% CI, 17 to 43), 
as compared with placebo. The 
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number of patients who need to 
be treated to prevent one case of 
diabetes over a 3-year period was 
6.9 with the lifestyle-interven-
tion program and 13.9 with met-
formin.
Through our own research, 
we have found that financial in-
centives for smoking cessation are 
highly effective, tripling smoking-
cessation rates at 9 to 12 months 
and resulting in “quit rates” that 
are 2.6 times those achieved with 
a control treatment at 15 to 18 
months, 6 months after the ter-
mination of the incentive pro-
gram.2 To illustrate the impor-
tance of comparing behavioral 
therapies with “standard therapy” 
for smoking cessation, we com-
pared our results with those pub-
lished in three recent meta-analy-
ses of placebo-controlled trials of 
medical therapies for smoking 
cessation, such as Zyban (bupro-
pion), Chantix (varenicline), and 
nicotine-replacement therapies 
(gum, patches, spray, lozenges, 
and inhalers).3-5 We were interest-
ed in how the benefits of pharma-
cologic therapies compared with 
those of financial incentives in 
terms of the pooled odds ratios 
for 12 months of continuous ab-
stinence (see graph).
This example highlights the 
value of including behavioral ap-
proaches in comparative studies: 
incentives appear to be at least 
as effective as pharmacologic aids 
in helping smokers to achieve 
long-term abstinence. Incentives 
may also be more cost-effective 
than medications, since they are 
paid only to smokers who suc-
ceed in quitting, whereas many 
patients who take medications for 
smoking cessation are unsuccess-
ful. Such a comparison, however, 
is no substitute for trials directly 
comparing the effectiveness of 
treatments. Different studies may 
have different quit rates because 
of the composition of the study 
population. We focused on the 
ratio of the quit rates in the treat-
ment group and the control group 
in each study rather than directly 
comparing the quit rates between 
studies. The effectiveness of a giv-
en treatment may also vary with 
the population being studied, 
and direct, head-to-head compar-
isons of different approaches are 
needed.
On the population level, the 
behavior of the health care deliv-
ery system itself is another im-
portant factor in health outcomes 
whose effects are not captured 
in traditional CER. For instance, 
the recently released report by the 
Institute of Medicine on residents’ 
duty hours and patients’ safety 
(Resident Duty Hours: Enhancing Sleep, 
Supervision, and Safety) highlighted 
a number of policy interventions 
that are believed to affect pa-
tients’ outcomes. Such interven-
tions are rarely subjected to the 
same level of scrutiny as medi-
cal treatments, though variations 
in certain aspects of care deliv-
ery — such as use of electronic 
medical records, weekend and 
overnight staffing, and the work 
intensity of health care providers, 
their cross-coverage patterns, and 
the numbers of continuous hours 
and hours per week that they 
work — can have a tremendous 
effect on patients’ safety. If the 
CER initiative is intended to im-
prove the health of populations, 
some portion of the research ef-
forts should focus on the relative 
effectiveness of system-level chang-
es in improving outcomes for a 
population of patients. Such ef-
forts could include hospital-based, 
regional, or national quality- 
improvement interventions; be-
havioral economic interventions, 
such as changing default options 
(e.g., automatically providing 90-
day, rather than 30-day, refills 
of prescriptions for chronic con-
ditions); efforts using incentives 
to steer patients toward short-
term decisions that are in their 
long-term best interest; and var-
ious regulatory, policy, or legis-
lative approaches.
Several examples highlight the 
power that such approaches may 
have in achieving changes in 
health outcomes. For example, the 
scarcity of organs for transplanta-
tion could be addressed through 
an “opt-out” approach similar to 
those used by many Western Euro-
pean countries; countries in which 
an “opt-out” approach is used 
typically have  organ-donation 
rates above 90%, whereas coun-
tries with an “opt-in” approach 
typically have rates of 5 to 15%, 
according to a 2003 study by 
Johnson and Goldstein. It is un-
likely that any non–policy-based 
approach could ever achieve such 
an increase in rates. In another 
example — to return to smoking 
cessation — perhaps the most ef-
fective (and probably most cost-
effective) way to reduce the rate of 
smoking, especially among young 
people, is to raise excise taxes.
In general, CER is a public 
good that has the potential to 
greatly inform the decisions of in-
dividual clinicians, patients, policy-
makers, and insurance plans in 
guiding the American people to 
preferentially use more-effective 
treatments. The full potential of 
this effort will be realized only if 
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we define problems broadly and 
include in these comparisons 
rigorous testing of behavioral 
and policy-based approaches to 
improving the health of popula-
tions.
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